The biopharmaceutical market is facing a new phase. Some of the most profitable biologic drugs are losing their patent protection, opening up a global market estimated at over $19 billion for biosimilars, otherwise known as "follow-on biologics" or "biogenerics." With this industry revolution, traditional business models have to change as a whole new set of global competitors emerge. As the industry moves forward, many wonder: What will the future of biopharmaceuticals look like?
Dr. Williams Ettouati is currently the Director, Industry Relations and Development and a Health Sciences Associate Clinical Professor at the Skaggs School of Pharmacy and Pharmaceutical Sciences (SSPPS) at the University of California, San Diego. Dr. Ettouati's role at the Skaggs School of Pharmacy is to develop and secure strategic collaborations with pharmaceutical and biotechnology companies, ranging from drug discovery to corporate sponsored fellowships for Pharm.D. students. In addition, Dr. Ettouati co-chairs a new course in Drug Discovery, Development & Commercialization for students from the Skaggs School of Pharmacy & Pharmaceutical Sciences, the Rady School of Management and the Medical School.
Before joining the Skaggs School of Pharmacy and Pharmaceutical Sciences, Dr. Ettouati spent twenty years in the pharmaceutical and biotechnology industry.
Dr. Ettouati received his Doctorât d’ État en Pharmacie from Université René Descartes, Paris V and a Master of Arts Biology, University of California, Santa Barbara.
This course is designed in collaboration with UC San Diego Skaggs School of Pharmacy.
